Sellas Life Sciences: A 600% Rally That Still Hangs on Two Unseen Events
Published on 07/11/2026 at 16:17 | Redaktion boerse-global.de
Sellas Life Sciences has emerged as one of the most electrifying — and nerve-wracking — names in the biotech space this year. The stock has surged nearly 600% over the past twelve months, yet its trajectory now depends on just two missing data points: the final events needed to trigger the database lock for its pivotal Phase 3 REGAL trial in acute myeloid leukemia.
On Friday, shares closed in Frankfurt at €11.30, down 4.64% on the day and 12.06% lower on the week. That pullback, however, barely dents a spectacular run: the stock has gained 82.26% over the past 30 days and remains about 26% below its 52-week high of €15.25, set on June 30. The disparity between the short-term volatility and the long-term rally underscores a market that is pricing both hope and uncertainty into every trade.
Analyst Sees Delay as a Bullish Signal
After the REGAL study recorded 78 of the 80 required events, the protracted wait for the final two has sparked debate. Alliance Global analyst James Molloy stepped in on July 6 with a dramatic upgrade, lifting his price target from $10 to $25 while maintaining a buy rating. His reasoning: the delay may indicate that patients in the control arm are living longer than expected — a scenario that would actually support the case for galinpimepimut-S, the drug under review.
That interpretation runs counter to earlier criticism that the study was dragging because newer therapies were prolonging survival in the control group. CEO Angelos Stergiou publicly rejected that narrative, arguing there is no approved maintenance therapy for a second complete remission in this setting. He also cautioned against valuing the company solely on potential sales of galinpimepimut-S, pointing to the broader pipeline, which includes the CDK9 inhibitor SLS009 also in development for leukemia.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
Institutional Interest and Retail Whiplash
The clinical drama has drawn a mix of sophisticated and speculative money. CoreCap Advisors disclosed a new, small position, while updated change-of-control clauses have fuelled chatter about possible partnerships or acquisition interest. At the other end of the spectrum, retail trading forums sent the stock sharply higher the previous week, only for those gains to evaporate without any fresh clinical news.
The market’s sensitivity to headline risk is extreme: Sellas’s annualized volatility over the past 30 days stands at 127%. With every tweet and analyst note moving the price, the shares are essentially trading on sentiment and positioning rather than fundamental metrics — at least until the trial data arrives.
Financial Cushion, Dilution Threat
The company’s recent quarterly report offers a mixed picture. Sellas posted a net loss of approximately $8.4 million for the period ended March 31, with EBITDA of negative $9.1 million. Yet the balance sheet shows resilience: roughly $107.1 million in cash and equivalents, and a current ratio above 17, provide enough runway to reach the trial readout.
That liquidity, however, comes with a caveat. A $150 million at-the-market (ATM) facility allows the company to issue new shares at any time, potentially diluting existing holders. Analysts flag the combination of ongoing cash burn and the ATM program as a risk, particularly if the trial outcome disappoints and the stock needs to raise capital at depressed levels.
Sellas Life Sciences at a turning point? This analysis reveals what investors need to know now.
Technical Support and the Final Wait
On the technical side, the 50-day moving average at €7.81 has acted as a floor during the recent rally, while the 200-day average at €3.99 — far below current levels — underscores the magnitude of the move. Should the REGAL results prove positive, the €15.25 year high could come back into play. But until the two remaining events occur and the data lock is complete, the shares will remain a play on binary outcomes.
For now, the countdown continues. Every passing day without those final two events either heightens anxiety or, as Molloy argues, strengthens the bull case. One way or another, the 80th event will break the deadlock — and determine whether this 600% rollercoaster has further to climb or a steep drop ahead.
Ad
Sellas Life Sciences Stock: New Analysis - 11 July
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
